ADIL Adial Pharmaceuticals, Inc.: רווח נקי למניה ב-12 החודשים האחרונים

The annual EPS (TTM) growth rate, based on GURU.Markets data, clearly demonstrates trends where the 46.30 metric determines this level. Adial Pharmaceuticals (ADIL) leverages its authority in addiction therapy through the safe drug AD04. Final-stage testing and expansion into Europe are driving growth. A patent shield and FDA certification costs ensure the company's exclusive dominance.
Adial Pharmaceuticals - פילוחים אנליטיים ומדדי מפתח (ADIL)

For Adial Pharmaceuticals (ADIL), the year-over-year (TTM) EPS comparison serves as a tool for monitoring capitalization efficiency. This metric measures the percentage change in net income per share over a rolling year. The calculation is based on the difference between the current and previous periods, identifying growth or decline rates in profitability. For a company in the drug development stage, this is a critical marker of the absence of stable cash flow. Any slowdown in this trend signals an increase in business risks.